Catalyst
Slingshot members are tracking this event:
PharmaMar (PHM.MC) Expects Data from Phase 3 Registration Trial in H2 2017 Evaluating Lurbinectedin (PM1183) in Platinum-Resistant Ovarian Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PHM.MC |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 11, 2017
Occurred Source:
http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
Related Projects
- A conversation with PharmaMar's Director of Oncology, Newly Hired COO, and Director of Capital Markets to discuss the upcoming pivotal year for the firm. PHM.MC, CLVS, TSRO Executed On: Mar 09, 2017 at 11:00 AM EST
Related Keywords
Phase 3, Registration Trial, Lurbinectedin, Pm1183, Platinum-resistant Ovarian Cancer
